+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective

Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective

Salud Publica de Mexico 51 Suppl 2: S191-S196

Genetic testing for mutations in BRCA1 and BRCA2 has potentially important public health implications. Through judicious testing of women believed to be at high risk for early-onset breast cancer and for ovarian cancer, it is possible to identify highly-predisposed women prior to the development of cancer. Current preventive options include preventive mastectomy, preventive oophorectomy, tamoxifen and oral contraceptives. The ability to offer genetic testing in Mexico on a widespread level is enhanced if the common founder mutations in the two genes can be discovered or if the cost of genetic sequencing is reduced. It is important that a genetic testing service be a multi-disciplinary effort with co-ordinated follow-up.

(PDF emailed within 1 workday: $29.90)

Accession: 055670688

Download citation: RISBibTeXText

PMID: 19967274

Related references

BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. Journal of Clinical Oncology 17(10): 3017-3024, 1999

Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes & Development 11(10): 1226-1241, 1997

BRCA1 and BRCA2 gene mutations and risk of breast cancer: Public health perspectives. American Journal of Preventive Medicine 16(2): 91-98, 1999

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Research 14(2): R66-R66, 2013

Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genetics in Medicine 7(1): 28-33, 2005

BRCA1 and BRCA2 Gene Mutations Screening In Sporadic Breast Cancer Patients In Kazakhstan. Central Asian Journal of Global Health 2(1): 29-29, 2018

Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clinical Cancer Research 9(10 Pt 1): 3606-3614, 2003

Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study. Cancer Epidemiology, Biomarkers & Prevention 15(3): 429-436, 2006

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Research 13(1): R20-R20, 2014

BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity. Medical Oncology 29(5): 3272-3281, 2013

BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Disease Markers 28(6): 377-384, 2010

Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. Clinical Genetics 72(4): 311-320, 2007

Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Research and Treatment 107(3): 431-441, 2007

Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations. Familial Cancer 10(2): 207-212, 2011

Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure. International Journal of Cancer 85(4): 474-481, Feb 15, 2000